Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-Cell tolerance

Melissa M. Berrien-Elliott, Stephanie R. Jackson, Jennifer M. Meyer, Craig J. Rouskey, Thanh Long M. Nguyen, Hideo Yagita, Philip D. Greenberg, Richard J. DiPaolo, Ryan M. Teague

Research output: Contribution to journalArticle

35 Scopus citations

Abstract

Tolerizing mechanisms within the host and tumor microenvironment inhibit T-cell effector functions that can control cancer. These mechanisms blunt adoptive immunotherapy with infused T-cells due to a complex array of signals that determine T-cell tolerance, survival, or deletion. Ligation of the negative regulatory receptors CTLA4, PD-1(PDCD1), or LAG3 on T-cells normally hinders their response to antigen through nonredundant biochemical processes that interfere with stimulatory pathways. In this study, we used an established mouse model of T-cell tolerance to define the roles of these inhibitory receptors in regulating CD8+ T-cell tolerance during adoptive immunotherapy to treat leukemia. Blocking CTLA4 and PD-1 in vivo combined to promote survival of transferred T-cells despite powerful deletional signals that mediate Bim (BCL2L11)-dependent apoptosis. However, this dual blockade was not optimal for stimulating effector function by responding T-cells, which required the additional blockade of LAG3 to induce full expansion and allow the acquisition of robust cytolytic activity. Thus, the cooperation of multiple distinct regulatory pathways was needed for the survival and effector differentiation of adoptively transferred tumor-reactive CD8+ T-cells. Our work defines the immune escape pathways in which simultaneous blockade could yield durable immunotherapeutic responses that can eradicate disseminated leukemia.

Original languageEnglish
Pages (from-to)605-616
Number of pages12
JournalCancer research
Volume73
Issue number2
DOIs
StatePublished - Jan 15 2013
Externally publishedYes

Fingerprint Dive into the research topics of 'Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8<sup>+</sup> T-Cell tolerance'. Together they form a unique fingerprint.

  • Cite this

    Berrien-Elliott, M. M., Jackson, S. R., Meyer, J. M., Rouskey, C. J., Nguyen, T. L. M., Yagita, H., Greenberg, P. D., DiPaolo, R. J., & Teague, R. M. (2013). Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-Cell tolerance. Cancer research, 73(2), 605-616. https://doi.org/10.1158/0008-5472.CAN-12-2179